Cancer cachexia: Developing multimodal therapy for a multidimensional problem
Introduction
Progress in the treatment of cancer cachexia has been slow. Contributory factors include the lack of a clear definition for cachexia, the multi-factorial nature of the condition, the lack of validated biomarkers, primitive clinical trial design and a paucity of interest by pharmaceutical/government sponsors of research. At present, the oncology community is divided between the majority who believe that weight loss is an inevitable consequence of progressive tumour growth versus a small minority who think that there is potential to significantly influence the patients’ nutritional status (and thereby improve the quality and the quantity of life) independent of tumour status. The former look to better ways of controlling tumour growth whilst the latter await well-conducted randomised trials on which to find an evidence-base to enact the change in clinical practice. The aim of this article is to determine whether there are grounds for optimism.
Section snippets
Classification of cachexia
It would be surprising to find that progress had been made in the treatment of a condition for which there was no clear definition. Sadly, there is no agreed classification of cancer cachexia. What can be said is that cachexia is a multidimensional syndrome that affects every compartment of the body and is most easily recognised in its advanced form by the severe loss of subcutaneous fat and skeletal muscle. Attempts by clinical trialists to define cachexia have focused generally at an earlier
Prevalence and impact of cachexia
Approximately one-quarter of all deaths in Western Society are due to cancer. Half of all patients with cancer lose some body weight; one-third lose more than 5% of their original body weight and up to 20% of all cancer deaths are caused directly by cachexia (through immobility, cardiac/respiratory failure).2, 3 The incidence of weight loss upon diagnosis varies greatly according to the tumour site. The highest prevalence of weight loss is seen amongst patients with solid tumours, e.g. gastric,
Pathophysiology of cachexia
Cancer patients lose weight as a result of reduced food intake (secondary to anorexia), abnormal metabolism or a combination of the two. For patients whose weight loss is predominantly due to anorexia, artificial nutritional support can be very successful. In this situation, the problem arises in balancing the use of invasive techniques against the preservation of the quality of life, in an individual whose lifespan is quite limited. However, this is not the situation in most cancer patients.
Biomarkers of cachexia
For the purposes of intervention trial design, there are a variety of novel biomarkers (Fig. 4) and end-points that should be considered. This area is developing rapidly and thus the following discussion is not exhaustive.
Novel end-points in cachexia intervention studies
Regulatory authorities are interested generally in a drug or treatment influencing favourably both body composition and physical function prior to licensing it for the treatment of cachexia. Until recently, it has been difficult for clinical investigators to provide accurate information on both domains. However, recent progress has opened new avenues.
Treatment options
Clearly, the best way to cure cachexia is to cure the cancer and a clear focus on optimal oncological management is important. It is also vital to recognise that comprehensive general medical management of the patient is essential to assess and treat secondary factors that might contribute to anorexia or metabolic decline. Thus, the pancreatic cancer patient with ongoing cholangitis, steatorrhoea or unrecognised diabetes is not going to respond to anti-cachexia therapy until he receives
Conclusions
There is an urgent need for further development of a formal definition of the cachexia spectrum and robust biomarkers of pre-cachexia and patient-oriented outcomes for cachexia randomised intervention trials. Recent advances in pathophysiology emphasise the need for improved food intake (especially protein), exercise and use of anti-inflammatory agents. Not all patients will respond equally. However, multimodal strategies to tackle both food intake and metabolic change have been demonstrated to
Conflict of interest statement
None declared.
References (70)
- et al.
Definition of cancer cachexia: effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis
Am J Clin Nutr
(2006) - et al.
Pathophysiology of cancer cachexia: much more than host–tumour interaction?
Clin Nutr
(2007) - et al.
Cancer cachexia and fatigue
Clin Med
(2006) - et al.
Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group
Am J Med
(1980) - et al.
Symptom prevalence in patients with incurable cancer: a systematic review
J Pain Symptom Manage
(2007) - et al.
Objective physical activity and self-reported quality of life in patients receiving palliative chemotherapy
J Pain Symptom Man
(2007) - et al.
Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies
Lancet Oncol
(2003) - et al.
Dystrophin glycoprotein complex dysfunction: a regulatory link between muscular dystrophy and cancer cachexia
Cancer Cell
(2005) Cancer cachexia: metabolic alterations and clinical manifestations
Nutrition
(1997)Sarcopenia: origins and clinical relevance
J Nutr
(1997)
Latency, duration and dose response relationships of amino acid effects on human muscle protein synthesis
J Nutr
Metabolic consequences of physical inactivity
J Ren Nutr
Fibrinogen synthesis is elevated in fasting cancer patients with an acute phase response
J Nutr
Do the differences between the amino acid compositions of acute-phase and muscle proteins have a bearing on nitrogen loss in traumatic states?
J Nutr
Increased expression of proteasome subunits in skeletal muscle of cancer patients with weight loss
Int J Biochem Cell Biol
The molecular mechanisms of skeletal muscle wasting: implications for therapy
Surgeon
Muscle protein breakdown and the critical role of the ubiquitin–proteasome pathway in normal and disease states
J Nutr
Clinical prognostic scoring system to aid decision-making in gastro-oesophageal cancer
Br J Surg
Weight gain prior to diagnosis and survival from breast cancer
Cancer Epidemiol Biomarkers Prev
‘The reflections you get’: an exploration of body image and cachexia
Int J Palliat Nurs
Cancer anorexia-cachexia syndrome: psychological effect on the patient and family
J Wound Ostomy Continence Nurs
Cancer-associated cachexia and underlying biological mechanisms
Annu Rev Nutr
Targets in clinical oncology: the metabolic environment of the patient
Front Biosci
Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia
Clin Cancer Res
Research methodology: cancer cachexia syndrome
Palliat Med
A critical assessment of the outcome measures and goals of intervention in cancer cachexia
Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers?
Br J Cancer
Hyperalimentation of the cancer patient with protein-calorie undernutrition
Cancer Res
Elevated tumour interleukin-1beta is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancer
Br J Cancer
Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients
Cancer Res
Characterization of a cancer cachectic factor
Nature
Cytokines in the pathogenesis of cancer cachexia
Curr Opin Clin Nutr Metab Care
Anabolic signaling deficits underlie amino acid resistance of wasting, aging muscle
FASEB J
Differential effects of hyperinsulinemia and hyperaminoacidemia on leucine–carbon metabolism in vivo. Evidence for distinct mechanisms in regulation of net amino acid deposition
J Clin Invest
Muscle protein synthesis measured by stable isotope techniques in man: the effects of feeding and fasting
Clin Sci
Cited by (348)
Blazing a trail in cancer cachexia care
2023, Asia-Pacific Journal of Oncology NursingThe impact of treatment-induced dysgeusia on the nutritional status of cancer patients
2023, Clinical Nutrition Open ScienceOvercoming barriers to timely recognition and treatment of cancer cachexia: Sharing Progress in Cancer Care Task Force Position Paper and Call to Action
2023, Critical Reviews in Oncology/HematologyThe barriers to interprofessional care for cancer cachexia among Japanese healthcare providers: A nationwide survey
2024, Journal of Cachexia, Sarcopenia and Muscle